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In 2016 WHO classification of CNS tumors genotypic and phenotypic param-
eters were integrated to define a new nomenclature of diffuse gliomas on the basis 
of presence or absence of isocitrate dehydrogenase mutations. This resulted in 
more homogenous and narrowly defined categories with better accuracy of prog-
nostic information, thus, playing a crucial role in patient management. Broadly, 
astrocytomas are now histologically and genetically distinct with IDH-mutant, 
ATRX-mutant, 1p/19q-intact and oligodendroglial tumors has IDH-mutant, ATRX-
wildtype and 1p/19q-codeleted profile. Glioblastoma are now classified into pri-
mary and secondary on the basis of IDH mutations independent of clinical history.
Keywords: Diffuse glioma, astrocytoma, oligodendroglioma, IDH, 1p/19q codeletion, 
ATRX, TERT, EGFR, PTEN, CDKN2A, MGMT, H3F3K27M
1. Introduction
In 2016 World Health Organization (WHO) classification of tumors of central 
nervous system, there was a paradigm deviation from earlier morphology based 
classification of gliomas to a new classification and nomenclature by integrating 
the molecular and histomorphological parameters. This approach provided finely 
defined diagnostic categories resulting in better correlation with prognostic and 
treatment parameters. Now diffuse gliomas whether astrocytoma or oligodendro-
glioma are grouped together on the basis of their shared IDH1 or IDH2 mutation 
status. Oligodendrogliomas also show 1p/19q codeletion. So, in 2016 diffuse glioma 
category comprise of WHO grade II and III astrocyctic tumors, grade II and III oli-
godendroglioma and grade IV glioblastoma, IDH mutant and wildtype. Continuing 
evolving knowledge on pathology of glioma led to a pediatric midline glioma with 
mutations in histone H3 genes to be also included with these adult diffuse gliomas. 
This excludes astrocytoma with circumscribed growth pattern and lacking IDH 
mutations i.e. pilocycytic astrocytoma, pleomorphic xanthoastrocytoma, subepen-
dymal giant cell astrocytoma. So, diffuse astrocytoma and oligodendrogliomas are 
now nosologically more similar than are diffuse astrocytoma and pilocytic astrocy-
toma and family tree of tumors is being redrawn [1].
This new classification was testament to rapid advancement in the field of 
molecular biology and reducing cost, easy availability for masses in the present 
times. Now there is possibility of detecting some of these mutations on immuno-
histochemistry. This journey from discovery of isocitrate dehydrogenase mutations 
peculiar to gliomas leading to their radical reclassification and new taxonomy based 




2.1 Isocitrate dehydrogenase mutations
Metabolism in cancer cells is rewired compared to normal cells since challenge is 
production more building blocks for proteins, nucleic acids rather than production 
of more ATP molecules as cell fuel. But very few tumors show mutations in genes 
directly involved in metabolic pathways. Isocitrate dehydrogenase (IDH) is an 
enzyme in the tricarboxylic acid (TCA) cycle of aerobic respiration and catalyzes 
the oxidative carboxylation converting isocitrate to α –ketoglutarate (α –KT). It 
exists in 3 isoforms i.e. IDH1, IDH2 and IDH3; isoenzymes are multiple forms of an 
enzyme catalyzing the same reaction but differ in amino acid sequence and kinetic 
properties (Table 1).
Only IDH 3 is a part of TCA cycle and dependent on nicotinamide adenine 
dinucleotide (NAD) as co factor [3–5].
Isocitrate + NAD+ → α-ketoglutarate + CO2 + NADH+ H+.
IDH 1 is found in cytosol and peroxisomes while IDH 2 in mito chondria,both 
using nicotinamide adenine dinucleotide phosphate (NADP) as cofactor. They 
both catalyze reversible reaction and prevent oxidative damage by generating 
NADPH [2].
Isocitrate + NADP+ ⇄ α -ketoglutarate + CO2 + NADPH+ H+.
In diffuse gliomas, heterozygous mutations seen in cytosolic IDH1 or mitochon-
drial IDH2 are considered as driver mutations [1–6]. Active site of both enzymes is 
formed by many arginine residues which is a polar amino acid. It forms hydrophilic 
bonds with isocitrate which is negatively charged. Most common mutation in diffuse 
gliomas is heterozygous point mutation at nucleotide position 395 of the IDH1 replaces 
guanine by adenine G395A resulting in replacement of arginine by histidine (less 
polar amino acid) at amino acid residue 132 of the protein (R132H). However, new 
enzyme IDH1-R132H homodimer is not completely inactive despite losing a critical 
substrate-binding amino acid residue. It gets a neomorphic activity resulting in reduc-
ing α-KG to D-2-hydroxyglutarate (D-2-HG) and oxidizing NADPH to NADP+ [3–5].
This mutation was first discovered in 2008 when next generation sequencing 
was used to study 22,661 protein coding genes in 22 glioblastomas and 5 of them 
IDH 1 IDH2 IDH3
LOCATION Cytosol Peroxisomes Mitochondria Mitochondria
COFACTOR NADP+ NADP+ NAD+
STRUCTURE Homodimer Homodimer Hetrooctamer  





MAJOR ROLE Prevent oxidative 
damage by generating 
NADPH
Prevent oxidative 
damage by generating 
NADPH
Catalytic role in TCA 
cycle (citric acid cycle)




Properties of three isoforms of IDH.
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showed expressed IDH mutations all at this same codon [2]. Subsequently, Yan 
and colleagues (26) analyzed IDH1 and IDH2 loci of nearly 1,000 central nervous 
system (CNS) tumors and found mutually exclusive mutations of IDH1 or IDH2 in 
more than 70% of WHO grade II and III astrocytomas and oligodendrogliomas and 
in secondary GBMs that developed from these lower-grade lesions [6]. Since then, 
numerous studies throughout the world substantiated the similar findings with het-
erozygous mutations in IDH 1 or less commonly in IDH2 been identified in nearly 
74% diffuse astrocytoma WHO grade II, 59% anaplastic astrocytoma WHO grade 
III, all secondary glioblastoma, 76% oligodendroglioma WHO grade II and 67% 
anaplastic oligodendroglioma WHO grade III. Most common hot spot mutations 
identified are R132C, R132S, R132G, R132L in IDH1 and R172K, R172M, R172W and 
R172G in IDH2 [1, 5].
Mechanism of oncogenesis of IDH is still under research. These IDH mutations 
result in metabolic dysregulation in tumor glial cells affecting glucose sensing, 
glutamine metabolism, lipogenesis, and regulation of cellular redox status. In 
normal cells, IDH 1and 2 wild type (wt) are an important source of NADPH. They 
are responsible for nearly 65% of total NADPH production in the cytoplasm of IDH 
wildtype (IDHwt) glioblastoma [3–5]. Glioma cells overexpressing IDH1-R132H or 
other mutations in IDH 1 or 2 had decreased NADPH levels so consequently, levels 
of reactive oxygen species (ROS) increased and GSH decreased. Apart from role of 
ROS, increased production of D-2-HG also has its implications on the tumor cell. 
D-2-HG and α-KG are structurally similar; only differ for the C2-linked oxygen 
atom in α-KG, which is replaced by a hydroxyl group in D-2-HG. So D-2-HG causes 
competitive inhibition of α-KG–dependent dioxygenases thus exerting its direct 
oncogenic effects. Approximately 60 dioxygenases regulate diverse and important 
cellular processes by hydroxylating target acceptor proteins by using α-KG as the 
donor substrate. Important among these are prolyl hydroxylases that regulate 
hypoxia-inducible factor (HIF) 1α, chromatin-modifying enzymes like histone 
N-methyl-lysine demethylases and ten-eleven translocations (TET) 5-methylcyto-
sine hydroxylases. The global histone demethylation by D-2-HG causes hypermeth-
ylation at a number of gene loci forming glioma-CpG island methylation phenotype 
and affect chromatin modification. D-2-HG also inhibits TET-mediated 5-meth-
ylcytosine hydroxylases levels which affect the expression of many regulatory 
proteins and possibly tumor suppressors that also contribute to tumorigenesis [5].
IDH mt gliomas can occur anywhere in the central nervous system but are pref-
erentially located supratentorially in the frontal lobes [1, 7, 8]. Hence it is hypoth-
esized IDH mt gliomas arise from a neural precursor population that is spatially and 
temporally restricted in the brain.
Since IDH mutations play a key role in tumourogenesis. Their diagnostic and 
prognostic role is well incorporated into routine neuropathology. IDH 1/2 muta-
tions can be detected by Direct Sanger sequencing, pyrosequencing, allele-specific 
hybridization polymerase chain reaction (PCR), Real-time PCR, digital droplet PCR 
and high-throughput next-generation sequencing. IDH1 R132H accounts for nearly 
90% of all IDH associated mutations in gliomas, so a monoclonal antibody has 
been developed against the mutant protein, allowing its use in paraffin-embedded 
specimens [1]. IHC IDH R132H mutation (clone H09) has shown sensitivity of 94% 
and a specificity of 100%. Positive staining is strong cytoplasmic and weak nuclear 
in tumor cells. Endothelial cells, perivascular lymphocytes, residual glial cells should 
be negative. Weak background staining and staining of macrophages is negative. 
Normal brain does not show staining for mIDH1 R132H IHC but granular staining in 
the neurons can be seen due to non specific binding to lipofuscin. One caveat to kept 
in mind while interpreting IHC is that macrophages can show strong cytoplasmic 
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granular staining even in IDH wt tumors. IHC is very useful for small samples where 
quantity of DNA extracted is too low for definite results by sequencing since it can 
highlight single infiltrating tumor cells [9]. IDH helps to separate gliosis (IDH nega-
tive) from low grade astrocytoma (IDH mt), if there is doubt in grade I and grade 
II glioma, IDH presence indicates we are dealing with grade II astrocytoma and also 
primary glioblastoma (IDH wt) from secondary glioblastoma (IDH mt). If IHC is 
negative, DNA sequencing is a must before calling a glioma IDH wt.
In all studies IDH mt gliomas have shown better improved progression free 
survival, longer time for treatment failure and extended overall survival in each 
of three treatment arms: radiotherapy, radiotherapy with PCV (procarbazine, 
lomustine and vincristine) or radiotherapy plus temozolomide [5]. So in addition 
to traditional good prognostic factors i.e. age < 40 years, lower tumor grade, tumor 
not crossing midline, absence of neurologic deficit before resection and tumor 
<6 cm, IDH mutation status has emerged as most important favorable prognostic 
factor in current times. Some studies have reported median survival of 10.9 years in 
IDH mt diffuse astrocytomas [1, 2, 6, 10].
Due to role of key role IDH mutations in glioma tumorogenesis, many isocitrate 
dehydrogenase inhibitors like hydroxypyridin-2-one, bis-imidazole phenol, tetra-
hydropyrazolopyridine are some of the drug under trails [5].
2.2 1p/19q codeletion
Nearly 60–80% of oligodendroglial neoplasms show co-deletion of 1p/19q: 
unbalanced translocation t(1;19)(q10;p10) after which only one copy of the short 
arm of chromosome 1 and one copy of the long arm of chromosome 19 remain 
and der (1;19) (q10;p10) is produced. It is hypothesized that translocation creates 
two derivative chromosomes, der(1;19)(p10;q10) and der(1;19)(q10;p10), and is 
followed by loss of the derivative chromosome containing 1p and 19q [11–16]. IDH 
wild type gliomas do not have 1p/19q codeletion.
Polysomy of 1p, 19q or both is also noted in a subset of oligodendrogliomas and 
has been associated with a poor prognosis, independent of deletion status [12, 13]. 
Oligodendrogliomas of grades II and III that have 1p/19q co-deletion also have a high 
frequency of TERT promoter mutations, CIC mutations on the remaining chromo-
some 1p allele and FUBP1 mutation on the remaining 19q allele (Figure 1) [14].
1p/19q codeletion are an essential part of molecular diagnostics of oligoden-
droglioma. Fluorescence in situ hybridisation (FISH), Cytogenomic microarray 
(CMA), Loss of heterozygosity and next generation sequencing are used to detect 
1p/19q co-deletion. FISH is a reliable and validated most commonly used labora-
tory technique among these. Normal cells show a 2O2G signal (two test and two 
control probes, test: control ratio = 1.0). Loss of a test signal yields a 1O2G signal 
pattern (ratio = 0.5) and represents absolute deletion of a chromosome. Presence 
of aneuploidy, polyploidy and polysomy affects the interpretation since it become 
unclear what percentage of nuclei are displaying genuine co-deleted signals, so a 
ratio is calculated dividing total number of test signals by total number of control 
signals. Atleast 60 non-overlapping nuclei are counted and ratio < 0.8 should be 
both chromosomes for 1p/19co-deletion. Ratio of 0.75–0.90 is considered  
borderline [11].
PCR-LOH analysis can be used for borderline cases, it has better specificity 
than FISH because it tests for multiple loci in a single assay. But PCR is more labour 
intensive, requires more tissue, a higher proportion of neoplastic cells (at least 
about 70%) [11].
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The 1p/19q codeletion confers a favorable prognosis and is predictive of 
responses to alkylating chemotherapy and combination of radiotherapy and  
chemotherapy [1, 11–16].
2.3 Alpha Thalassemia/Mental Retardation Syndrome X-linked (ATRX)
Another critical marker that defined molecular classification of gliomas is ATRX 
gene present on Xq21.1. It is named so since it was first discovered through a study 
of assessing patients with the X-linked mental retardation syndrome presenting 
with α-thalassemia, severe psychomotor impairments, urogenital abnormalities, 
and patterns of characteristic facial dysmorphism. This gene encodes a protein 
which belongs to a chromatin-remodeling pathway (ATRX-DAXX) and is required 
for genomic stability by the incorporation of H3.3 at telomeres [17]. ATRX inac-
tivation within gliomas can be due to mutations, deletions, gene fusions, or any 
combination of these. These mutations induce abnormal telomeres that are charac-
teristic of a telomerase-independent telomere maintenance mechanism termed ALT 
(alternative lengthening of telomeres) [18].
Numerous studies have shown that ATRX mutations have a strong association 
with IDH mutations but never with 1p/19q codeletion. This property is exploited 
as diagnostic marker since ATRX inactivation indicates astrocytic lineage and 
rules out oligodendroglioma. ATRX mutations can be detected by direct Sanger 
sequencing, pyrosequencing, allele-specific hybridization polymerase chain 
reaction (PCR), Real-time PCR and high-throughput next-generation sequenc-
ing. ATRX IHC: clone CL0537 when show loss of nuclear expression >90% tumor 
nuclei is indicative of mutated ATRX. Nuclei of non-neoplastic cells such as 
endothelia, microglia, lymphocytes and reactive astrocytes are strongly positive 
and serve as positive internal control. When tumor cells show retained nuclear 
expression of ATRX IHC it indicates wild type ATRX [1, 17–20].
Figure 1. 




Low-grade glioma patients with ATRX retention and IDH mutations have lower 
progression-free survival and overall survival (OS) than tumors with 1p/19q code-
letion and IDH mutations and longer time to treatment failure than those patients 
with IDH mutation and wild-type ATRX (55.6 vs. 31.8 months, respectively). Thus 
ATRX mutation infer a favorable prognosis to tumor [1, 19, 20].
2.4 TP53
Mutations of TP53 are found in over 60–80% of infiltrative astrocytomas, 
anaplastic astrocytomas and secondary GBMs, yet are rare in oligodendrogliomas.
There is a strong association between IDH1 mutation and TP53 mutation in dif-
fuse astrocytomas, and this combination of mutations is helpful in distinguishing 
astrocytomas from oligodendroglimas [1].
TP53 mutations can be analyzed by direct Sanger sequencing, pyrosequenc-
ing, PCR, allele-specific hybridization, real-time PCR and high-throughput 
next-generation sequencing. P53 IHC is also easily available and widely used. 
Immunostain reacts with both the normal and mutant forms of p53. Wild type 
P53 is rapidly degraded and has short half-life, hence is not detected by p53 
IHC. Mutant p53 degrade more slowly, accumulate within nucleus of tumor 
cells creating a stable target for IHC. IHC detection of overexpressed protein is 
thus used as a surrogate method for mutation analysis, But it is not sensitive or 
specific. Over the last 25 years, studies have shown concordance rates between 
p53 IHC and TP53 mutation status ranging from 55 to 89% in grade I–IV gliomas 
[1, 21, 22].
TP53 alterations are usually missense producing stable full-length protein. 
Nonsense, frameshift, or deletion mutations results in incomplete translation 
of p53 gene producing a truncated protein product or loss of protein expression. 
This anomalous p53 structure may not be recognized during p53 IHC analysis 
resulting in false negativity. Some studies considered >10% tumor nuclei stain-
ing as positive for TP53 mutation status while others consider >50% as positive 
[21, 22].
2.5 TERT promotor mutations
One of the hallmarks of cancer is its ability to proliferate indefinitely. In nor-
mal somatic cells, the number of cell division is limited by the telomere length 
of chromosomes as it decreases with each replicative cycle. Cancer cells often 
overcome this limit by activating their telomerase. Telomerase consists of an RNA 
subunit and a reverse transcriptase catalytic subunit (TERT), which adds telomeric 
repeats to chromosome ends, therefore, maintaining telomere length. TERT gene 
on 5p15.33 encodes catalytic active site of telomerase and one of the mechanisms 
of telomerase activation in gliomas is somatic mutations in the promoter region of 
TERT. Most common mutations are C228T and C250T. The frequency of mutation 
was nearly 72% of IDH wt glioblastomas and in 95% of IDH mt oligodendrogiomas 
while relatively low in diffuse astrocytomas and anaplastic astrocytomas (19 and 
25%, respectively) [23]. ATRX mutations are mutually exclusive of TERT gene 
mutations [1].
TERT mutations are detected by sequencing. IDH mutation, with 1p/19q codele-
tion and TERT mutation is characteristic of oligodendroglioma. TERT mutation in 
absence of IDH mutation indicates astrocytoma. In IDH wt gliomas, one with TERT 
mutation is associated with reduced overall survival compared to those lacking it. 
TERT mutation in IDH mt gliomas carries good prognosis [24].
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2.6 EGFR
Epidermal growth factor receptor (EGFR) is a transmembrane receptor tyrosine 
kinase, whose ligands include EGF and TGF-α. Most frequently amplified oncogene 
in astrocytic tumors. EGFR amplification is seen in nearly 40% of primary/ IDH wt 
glioblastoma and rarely in secondary/ IDH mt glioblastoma [1]. There are also spe-
cific EGFR mutations (the vIII mutant), which produce a truncated transmembrane 
receptor with constitutive activity. Both EGFR amplification and the EGFRvIII 
mutant are mutually exclusive with IDH mutations [25].
2.7 PTEN
Loss of large regions at 10p, 10q23 and 10q25–26 loci, or loss of an entire copy of 
chromosome 10 is the most frequent genetic alterations in primary glioblastoma. It 
is specific for astrocytic differentiation and are rare in oligodendrogliomas [25].
2.8 CDKN2A:
Cyclin-dependent kinase inhibitor 2A (CDKN2A) is a gene located at chromo-
some 9, band p21.3. CDKN2A homozygous deletion is associated with poor progno-
sis among IDH-mutant gliomas [26, 27].
2.9 MGMT methylation
MGMT (O6-methylguanine-DNA methyltransferase) is a DNA repair enzyme 
and reverses the damage caused by alkylating agent temozolomide(TMZ) which 
adds methyl group at O6 position of guanine and this alkylation forms cross-links 
between adjacent strands of DNA. The MGMT protein rapidly reverses alkylation 
at the O6 position of guanine thereby averting the formation of lethal cross-links 
resulting in TMZ resistance. Promotor methylation of MGMT inactivates the gene 
so patients with MGMT promotor methylation are more benefitted with TMZ than 
patients without it [28].
MGMT promotor methylation is an essential part of molecular workup of 
all grade III and IV gliomas. Promoter methylation of O6-methylguanine–DNA 
methyltransferase (MGMT) is detected by methylation specific PCR, pyrosequenc-
ing or array based studies. MGMT determination by immunohistochemistry lacks 
standardization, reproducibility and, most importantly, correlation with clinical 
outcome so it is no longer recommended.
MGMT promotor methylation is commonly associated with IDH mutations and 
genome wide epigenetic changes (G-CIMP).
3. Diffuse gliomas
Difuse astrocytoma, IDH mutant, and WHO grade II: Diffuse astrocytoma 
composed of well differentiated fibrillary astrocytes in loose microcystic matrix. 
They show nuclear atypia in the form of variation in nuclear shape or size with 
accompanying hyperchromasia. All show mutation in IDH 1 or IDH2 supported by 
presence of ATRX characterized by gemistocytes forming nearly 20% of the tumor 
cells is a variant of IDH mt diffuse astrocytoma [1, 29, 30].
Difuse astrocytoma, IDH wild type, and WHO grade II: diffusely infiltrating 
astrocytoma without mutations in the IDH genes. It is extremely rare.
CNS Malignancies
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Anaplastic astrocytoma, IDH mutant: Diffusely infiltrating astrocytoma with 
focal or dispersed anaplasia, significant mitotic activity and mutation in IDH 1 or 
IDH. TP53 or ATRX mutations are found in majority of tumors.
Glioblastoma, IDH wild type/ primary glioblastoma: They are high grade 
astrocytoma with nuclear atypia, cellular pleomorphism, mitosis, microvascular 
proliferation and necrosis. They lack IDH mutations but show TERT promotor 
mutations (80% cases), homozygyous deletion of CDKN2A/CDKN2B (60% cases), 
loss of chromosome 10p (50% cases), 10q (70%), EGFR alterations (55% cases) and 
PTEN (40% cases) [14, 15]. They account for nearly 90% of all glioblastoma [1].
Glioblastoma, IDH mutant/ secondary glioblastoma: IDH mutations in glio-
blastomas are considered as a marker for glioblastoma that arise by transformation 
from lower-grade gliomas, regardless of clinical history. IDH mt/secondary glio-
blastomas differ from IDH wt/primary glioblastoma in preferential frontal location 
and lesser extent of necrosis. Radiologically IDHmt glioblastoma exhibited more 
frequent non-enhancing tumor component, larger size at diagnosis, lesser extent of 
edema, and increased prevalence of cystic and diffuse components [31, 32]. Median 
age of IDHmt glioblastoma at diagnosis is 43 years while that of primary IDH wt 
glioblastoma is nearly 60 years [1].
Hence in routine histopathology practice, for older patients >55 years old, glio-
blastoma not in midline location and no prior history of lower grade glioma, IDH 
wt type designation can be given solely on the basis of negative IDH R132H immu-
nohistochemistry. Sequencing is not required as the probability of an alternate IDH 
mutation is <1% [1, 31, 32].
IDH mt glioblastoma manifest longer overall survival and showed more frequent 
promoter methylation of MGMT [6].
Oligodendroglioma: Diffusely infiltrating slow growing glioma composed of 
monomorphic cells with uniform round nuclei and variable perinuclear haloes with 
IDH1 or IDH2 mutation and codeletion of chromosomes arms 1p and 19q.
IDH mutant gliomas which do not show ATRX loss on IHC should be considered 
for 1p/19qcodeletion studies even in absence of clear cut oligodendroglial  
histology [33].
Rarely tumors with oligodendroglial morphology but lacking IDH mutations 
or 1p/19q codeletion are noted. This group belongs to pediatric type oligoden-
droglioma. It is important to rule out histological mimics like dysembryoplastic 
neuroectodermal tumor, extraventricular neurocytoma, clear cell ependymoma and 
pilocyctic astrocytoma before rendering diagnosis of pediatric type oligodendro-
glioma [34, 35]. They show FGFR1 duplications or rearrangements of MYB related 
MYBL1 translocation [33].
Tumors with 1p/19 q codeletion without IDH mutations are usually IDH wt high 
grade astrocytomas and must be evaluated for possibility of incomplete deletion of 
on 1p and 19q [1].
Diffuse midline glioma: They are Infiltrative midline high grade glioma with 
astrocytic differentiation and mutations in histone proteins. Pons, thalamus, spinal 
cord are the common locations. Median age is 5–11 years. They are always IDH 
wild type and are considered grade IV tumors. In humans, there are main three 
histone H3 proteins: H3.1 encoded by HIST1H3B and HIST1H3C, H3.2 encoded 
by HIST2H3C and H3.3 encoded by H3F3A and H3F3B. Most common histone 
mutation is H3K27M (lysine to methionine substitution in H3F3A gene) which 
inhibits trimethylation of H3.3 histone resulting in decrease in H3K27me3. Other 
less frequent mutations occur in HIST1H3B or HIST1H3C. This can be detected 
by Sequencing for H3F3A and HIST1H3B. However, monoclonal H3F3A K27M 
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antibody is also available and intense nuclear staining in more than 80% of cells is 
taken as positive. Concordance between immunohistochemistry and sequencing is 
nearly 95%. H3 K27M mutated tumors show loss of H3K27me3 staining which can 
also be detected by IHC but it is not specific [1, 36].
Not otherwise specified (NOS) designation: It is used in tumors when either 
molecular testing is not available (e.g., in low-resource settings), or was performed 
but did not yield adequate results (assay failure), or was deliberately not done 
(e.g., not testing IDH status in an elderly patient with glioblastoma because of lack 
of implications for therapeutic management. But when molecular tests have been 
performed but results do not lead to a precise categorization of the tumor within 
the framework of the WHO 2016 classification, then term not elsewhere classified 
(NEC) is used [1, 26].
Final histopathological report:
• Layer 1: Integrated diagnosis
• Layer 2: Histological classification (i.e. cellularity, mitosis, necrosis, vascular 
endothelial proliferations, variants)
• Layer 3: Histologic (WHO) grade (based on morphology)
• Layer 4: Biomarker studies (IDH, ATRX, p53, 1p/19q codel, EGFR)
Example:
• Integrated diagnosis: Diffuse Astrocytoma IDH mt, WHO grade II
• Histological diagnosis: Diffuse astrocytoma, WHO (histological) grade II
• Molecular information:
• IDH: positive (R132H immunohistochemistry; consistent with mutant type)
• ATRX: nuclear expression loss (immunohistochemistry; consistent with 
mutant type)
• p53: positive, >60% (immunohistochemistry; consistent with mutant type)
Key points
• Astrocytoma= IDH+/ATRX loss / mutated TP53
• Oligodendroglioma = IDH mutant/ATRX retained/1p/19q co-deleted
• Primary GBM: no IDH mutation/ EGFR/ TERT/PTEN/ TP53
• Secondary GBM: IDH+/ATRX loss / mutated TP53
• ATRX mutations are strongly associated with IDH mutations and are mutually 
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